$OTLC
Oncotelic Therapeutics, Inc.

2017 Q3 Form 10-Q Financial Statement

#000119312517245861 Filed on August 02, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $710.0K $880.0K $1.300M
YoY Change -40.34% -32.31% -3.7%
% of Gross Profit
Research & Development $2.832M $3.019M $2.374M
YoY Change 36.48% 27.17% 19.84%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $3.540M $3.896M $3.670M
YoY Change 8.52% 6.16% 10.28%
Operating Profit -$3.540M -$3.896M -$3.670M
YoY Change 8.52% 6.16% 10.28%
Interest Expense $10.00K $10.00K $30.00K
YoY Change -66.67% -66.67% 200.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K $0.00 $0.00
YoY Change -100.0%
Pretax Income -$3.540M -$3.880M -$3.640M
YoY Change 9.26% 6.59% 9.64%
Income Tax
% Of Pretax Income
Net Earnings -$3.536M -$3.884M -$3.641M
YoY Change 9.27% 6.67% 9.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.15 -$0.14
COMMON SHARES
Basic Shares Outstanding 26.54M shares 26.54M shares 26.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.910M $5.000M $19.34M
YoY Change -88.27% -74.15% -41.55%
Cash & Equivalents $1.908M $5.004M $7.939M
Short-Term Investments $0.00 $0.00 $11.40M
Other Short-Term Assets $1.030M $1.490M $1.040M
YoY Change 10.75% 43.27% 121.28%
Inventory
Prepaid Expenses $772.0K $1.162M
Receivables
Other Receivables
Total Short-Term Assets $2.938M $6.490M $20.38M
YoY Change -82.93% -68.15% -39.29%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000K $6.000K $19.00K
YoY Change -71.43% -68.42% -54.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K $33.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $37.00K $39.00K $52.00K
YoY Change -21.28% -25.0% -30.67%
TOTAL ASSETS
Total Short-Term Assets $2.938M $6.490M $20.38M
Total Long-Term Assets $37.00K $39.00K $52.00K
Total Assets $2.975M $6.529M $20.43M
YoY Change -82.76% -68.04% -39.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $312.0K $401.0K $501.0K
YoY Change -41.35% -19.96% 181.46%
Accrued Expenses $900.0K $1.020M $1.120M
YoY Change -5.26% -8.93% 13.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.211M $1.425M $1.617M
YoY Change -18.45% -11.87% 38.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.211M $1.425M $1.617M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.210M $1.430M $1.620M
YoY Change -18.79% -11.73% 38.46%
SHAREHOLDERS EQUITY
Retained Earnings -$289.8M -$286.3M -$271.8M
YoY Change 5.39% 5.35% 5.65%
Common Stock $291.6M $291.4M $290.6M
YoY Change 0.28% 0.28% 0.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.764M $5.104M $18.81M
YoY Change
Total Liabilities & Shareholders Equity $2.975M $6.529M $20.43M
YoY Change -82.76% -68.04% -39.27%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$3.536M -$3.884M -$3.641M
YoY Change 9.27% 6.67% 9.54%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.100M -$3.340M -$3.540M
YoY Change 0.98% -5.65% 35.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.300M $1.210M
YoY Change -100.0% 90.08%
Cash From Investing Activities $0.00 $2.300M $1.210M
YoY Change -100.0% 90.08% -6150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.100M -3.340M -3.540M
Cash From Investing Activities 0.000 2.300M 1.210M
Cash From Financing Activities 0.000
Net Change In Cash -3.100M -1.040M -2.330M
YoY Change 11.51% -55.36% -12.08%
FREE CASH FLOW
Cash From Operating Activities -$3.100M -$3.340M -$3.540M
Capital Expenditures $0.00
Free Cash Flow -$3.540M
YoY Change 34.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7939000
CY2017Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
483000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
6490000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291144000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
401000
CY2017Q2 us-gaap Assets
Assets
6529000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
5004000
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
5004000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5004000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9626000 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
265000
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6529000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1425000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
421000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
324000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1162000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-286305000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2000000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.90
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
785000 shares
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4219000 shares
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.89
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4540000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5941000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.01
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
5104000
CY2017Q2 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
120000
CY2017Q2 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
1722000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27285000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
842000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
14070000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290698000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
310000
CY2016Q4 us-gaap Assets
Assets
14114000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
12047000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
12047000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3535000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
265000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14114000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1614000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
398000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1946000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278463000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
549000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4177000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.47
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
8512000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
12500000
CY2016Q4 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
64000
dei Amendment Flag
AmendmentFlag
false
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1469000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
5000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Entity Registrant Name
EntityRegistrantName
MATEON THERAPEUTICS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000908259
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1999000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-189000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-537000
us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8512000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7043000
us-gaap Operating Expenses
OperatingExpenses
7866000
us-gaap Net Income Loss
NetIncomeLoss
-7842000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7866000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
8512000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5867000
us-gaap Share Based Compensation
ShareBasedCompensation
446000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M0D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y2M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
720000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2484000 shares
us-gaap Substantial Doubt About Going Concern Managements Evaluation
SubstantialDoubtAboutGoingConcernManagementsEvaluation
The Company’s existing cash and cash equivalents to support its operations only into October 2017. Prior to this time, the Company will need to secure additional funding or it could be forced to curtail or terminate its drug development programs and its operations. Because the Company does not currently have a source of working capital that will sustain its planned operations past October 2017, Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern.
us-gaap Substantial Doubt About Going Concern Conditions Or Events
SubstantialDoubtAboutGoingConcernConditionsOrEvents
Any additional equity financing, if available, may not be available on favorable terms and would most likely be dilutive to current stockholders.
dei Trading Symbol
TradingSymbol
OXGN
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
-720000 shares
oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
2484000 shares
oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y3M19D
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P7Y8M23D
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
1.29
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19346000
us-gaap Depreciation
Depreciation
11000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2668000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-486000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
930000
us-gaap Investment Income Interest
InvestmentIncomeInterest
57000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11402000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7944000
us-gaap Operating Expenses
OperatingExpenses
7022000
us-gaap Net Income Loss
NetIncomeLoss
-6966000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7022000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15604000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
4202000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4354000
us-gaap Share Based Compensation
ShareBasedCompensation
427000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M0D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3884000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3896000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3019000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
3896000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1296000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
3670000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3641000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3670000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2374000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
877000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares

Files In Submission

Name View Source Status
0001193125-17-245861-index-headers.html Edgar Link pending
0001193125-17-245861-index.html Edgar Link pending
0001193125-17-245861.txt Edgar Link pending
0001193125-17-245861-xbrl.zip Edgar Link pending
d419456d10q.htm Edgar Link pending
d419456dex311.htm Edgar Link pending
d419456dex312.htm Edgar Link pending
d419456dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oxgn-20170630.xml Edgar Link completed
oxgn-20170630.xsd Edgar Link pending
oxgn-20170630_cal.xml Edgar Link unprocessable
oxgn-20170630_def.xml Edgar Link unprocessable
oxgn-20170630_lab.xml Edgar Link unprocessable
oxgn-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending